Topoisomerase enzymes as drug targets

Current Opinion in Oncology

Volumn 11, Issue 6, 1999, Pages 482-489

  Guichard, Sylvie M ^a   Danks, Mary K ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; HELICASE; IRINOTECAN; NUCLEOLIN; PHOSPHOTRANSFERASE; RNA POLYMERASE II; VINCRISTINE; VIRUS T ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLON CANCER; DNA STRUCTURE; DRUG DOSE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIMIAN VIRUS 40; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS;

EID: 0032700246     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199911000-00009     Document Type: Short Survey

References (70)

1. 1 Biochim Biophys Acta 1998, 1400 (1-3):1-354. This entire volume contains excellent reviews on all aspects of topoisomerases I and II.
2. 2 Takimoto DH, Wright J, Arbuck SG: Clinical applications of the camptothecins. Biochim Biophys Acta 1998, 1400:107-119.
3. 3 Hande KR: Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998, 1400:173-184.
4. 4 Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D: DNA topoisomerase I is involved in both repression and activation of transcription. Nature 1993, 365:227-232.
5. 5 Haluska Jr P and Rubin EH: A role for the amino terminus of human topoisomerase I. Advan Enzyme Regul 1998, 38:253-262.
6. 6 Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, et al.: Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996, 381:80-82.
7. nrb control DNA-topoisomerase I activity by a direct interaction. J Biol Chem 1998, 41:26261-26264.
8. 8 Gobert C, Bracco L, Ross F, Olivier M, Tazi J, Lavelle F, et al.: Modulation of DNA topoisomerase I activity by p53. Biochem 1996, 35:5778-5786.
9. 9 Wang A, Roeder RG: DNA topoisomerase I and PC4 can interact with human TFIIIC to promote both accurate termination and transcription reinitiation by RNA polymerase III. Mol Cell 1998, 1:749-757.
10. 10 Rossi R, Labourier E, Gallouzi I-E, Derancourt J, Allemand E, Divita G, Tazi J: The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity. Nuc Acids Res 1998, 26:2963-2970.
11. 11 Ciavarra RP, Goldman C, Wen KK, Tedeschi B, Castora F: Heat stress induces hsc70/nuclear topoisomerase I complex formation in vivo: evidence for hsc70-mediated, ATP-independent reactivation in vitro. Proc Natl Acad Sci USA 1994, 91:1751-1755.
12. 12 Shuman S. Polynucleotide ligase activity of eukaryotic topoisomerase I. Mol Cell 1998, 1:741-748.
13. 13 Simmons DT, Roy R, Chen L, Gai D, Trowbridge PW: The activity of topoisomerase I is modulated by large T antigen during unwinding of the SV40 origin. J Biol Chem 1998, 273:20390-20396.
14. 14 Simmons DT, Trowbridge PW, Roy R: Topoisomerase I stimulates SV40 T antigen-mediated DNA replication and inhibits T antigen's ability to unwind DNA at nonorigin sites. Virology 1993, 242:435-443.
15. 15 Pommier Y, Kohlhagen G, Wu C, Simmons DT: Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by Simian virus 40 large T antigen. Biochem 1998, 37:3818-3823.
16. 16 Bharti AK, Olson OJ, Kufe DW, Rubin EH: Identification of a nucleolin binding site on human topoisomerase I. J Biol Chem 1996, 271:1993-1997.
17. 17 Labourier E, Rossi R, Gallouzi I-e, Allemand E, Divita G, Tazi J: Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor. Nuc Acids Res 1998, 26:2955-2962.
18. 18 Champoux JJ: Domains of human topoisomerase I and associated functions. Prog Nuc Acid Res 1998, 60:111-132.
19. 19 Gromova I, Biersack H, Jensen S, Nielsen OF, Westergaard O, Andersen AH: Characterization of DNA topoisomerase α/β heterodimers in HeLa cells. Biochem 1998, 37:16645-16652.
20. 20 Gardiner LP, Roper DI, Hammonds TR, Maxwell A: The N-terminal domain of human topoisomerase llα is a DNA-dependent ATPase. Biochem 1998, 37:16997-17004.
21. 21 Bojanowski K, Maniotis AJ, Plisov S, Larsen AK, Ingber DE: DNA topoisomerase II can drive changes in higher order chromosome architecture without enzymatically modifying DNA. J Cell Biochem 1998, 69:127-142.
22. 22 Bhat UG, Raychaudhuri P, Beck WT: Association of topoisomerase Ha with the retinoblastoma protein in human cell lines. Proc Am Assoc Cancer Res 1999, 40:209.
23. 23 Gieseler F, Kurz EU, Clark M, Leader KB, Kroll DJ: Interaction between DNA topoisomerase llα and 14-3-3ε modulates sensitivity to etoposide. Proc Am Assoc Cancer Res 1999; 40:209.
24. 24 Pommier Y, Pourquier P, Fan Y, Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998, 1400:83-106.
25. 25 Labourier E, Riou JF, Prudhomme M, Carrasco C, Bailly C, Tazi J: Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res 1999, 59:52-55. R-3 is a unique topoisomerase I inhibitor in that it induces formation of covalent complexes of the enzyme with DNA and inhibits the kinase activity of the enzyme.
26. 26 Lee J-H, Lee J-M, Kim J-K, Ahn S-K, Lee S-J, Kim M-Y, et al.: Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998, 21:581-590.
27. 27 Kumaza E, Jimbo T, Ochi Y, Tohgo A: Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Phamacol 1998, 42:210-220.
28. 28 Weitman S, DeJager R, Marty J, Barrera H, Morre R, VonHoff D; Preclinical evaluation of DX-8951f against pediatric solid tumors. Proc Am Soc Clin Oncol 1999, 18:198a.
29. 29 Geyer C, Hammond L, Johnson T, Smetzer L, Coyle J, Drengler R, VonHoff D, et al.: Dose-schedule optimization the hexacyclic camptothecin analog DX-8951f: A Phase I and pharmacokinetic study with escalation of both treatment duration and dose. Proc ASCO 1999, 18:212a.
30. 30 Rowinsky E, Johnson T, Geyer C, Eckhardt SG, Smetzer L, Coyle J, et al.: DX-8951f, a hexacyclic camptothecin analog on a daily × 5 day schedule: A Phase I and pharmacokinetic study. Proc ASCO 1999, 18:164a.
31. 31 Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu Boue A, Houghton JA: Therapeutic efficacy of the topoisomerase inhibitor 7-ethey-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993, 53:2823-2829.
32. 32 Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36:393-403.
33. 33 Vassal G, Boland I, Santos A, Bissery M-C, Terrier-Lacombe M-J, Morizet J, et al.: Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 1997, 73:156-163.
34. 34 Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993, 53:725-727.
35. 35 Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF: Phenytoin alters the disposition of topotecan and N-desmethyltopotecan in a patient with medulloblastoma. Clin Cancer Res 4:783-789.
36. 36 Friedman HS, Kerby T, Fields S, et al.: Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 1999, 84:1160-1165.
37. 37 Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al.: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
38. 38 Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP: 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma Cancer 1997, 80:1727-1732.
39. 39 Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993, 53:863-871.
40. 40 Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 1993, 5:273-281.
41. 41 Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210-221.
42. 42 Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, et al.: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995, 6:133-140.
43. 43 Rothenberg ML, Kuhn JG, Burris HA, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194-2204.
44. 44 Merrouche Y, Extra JM, Abiegerges D, Bugtat R, Catimel G, Suc E, et al.: High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients:a feasibility study. J Clin Oncol 1997, 15:1080-1086.
45. 45 Vassal G, Droz F, Frappaz D, Taibi A, Namouni F, Santos A, et al.: A Phase I trial of irinotecan (CPT-11) in children. Proc ASCO 1999, 18:563a.
46. 46 Blaney S, Berg S, Pratt C, Vietti T, Sullivan J, Murry D, Bernstein M: A Phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group study. Proc ASCO 1999, 18:198a.
47. 47 Furman WL, Stewart CF, Pratt CB, Santana VM, Bowman LB, Ma MK, et al.: A Phase I study of irinotecan (CPT-11) in children with relapsed solid tumors. Proc ASCO 1998, 17:187a.
48. 48 Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, et al.: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998, 4:743-753.
49. 49 Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, et al.: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999, 17:685-696. This clinical study confirmed preclinical observations that a greater SN-38/CPT-11 AUC was achieved with oral compared with intravenous administration of CPT-11.
50. 50 Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, et al.: Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998, 16:2233-2237. This clinical study is an excellent example of the schedule-dependent effects (antitumor effect as well as toxicity) of the camptothecin analogue topotecan.
51. 51 Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, et al.: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999, 5:69-75.
52. 52 Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, et al.: Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refracory lymphomas. J Clin Oncol 1998, 16:2345-2351.
53. 53 Langevin AM, Casto DT, Thomas PJ, Weitman SD, Kretschmar C, Grier H, et al: Phase I trial of 9-aminocamtothecin in children with refractory solid tumors: A Pediatric Oncology Group study. J Clin Oncol 1998, 16:2494-2499.
54. 54 deJonge MJ, Sparreboom A, Verweij J: The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat Rev 1998, 24:205-220.
55. 55 Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P: Sequence-dependent activity of the irinotecan-5-FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997, 73:729-734.
56. 56 Douillard JY, Cunningham AD, Roth AD, Germa JR, James RD, Karasek P, et al: A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy. Proc ASCO 1999, 18:233a.
57. 57 Goldwasser F, Valenti M, Torres R, Kohn KW, Pommier Y: Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin Cancer Res 1996, 2:687-693.
58. 58 Saltz L, Kanowitz J, Kelsen D, et al.: Phase I study of weekly cisplatin (CDDP) plus irinotecan (CPT-11) in patients with advanced solid tumors. Proc ASCO 1996, 15:A1540.
59. 59 Rowinsky EK, Kaufmann SH, Baker SD: Sequences of topotecan and cisplatin: Phase I, pharmacology, and in vitro studies to examine sequence dependence. J Clin Oncol 1996, 14:3974-3084.
60. 60 Mori K, Machida S, Yoshida T, Yoshida M, Kano Y, Tominaga K: A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1999, 43:467-470.
61. 61 Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, et al.: Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small cell lung cancer. Br J Cancer 1997, 76:1494-1499.
62. 62 Herben VM, ten Bokkel Huinink WW, Dubbelman AC, Mandjes IA, Groot Y, van Gortel-van Zomeren DM, Beijnen JH: Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997, 76:1500-1508.
63. 63 Thompson J, Guichard S, Danks MK, Bodner S, Houghton PJ: Synergistic activity of topotecan and vincristine in a model of disseminated neuroblastoma in SCID mice. Proc Am Assoc Cancer Res 1999, 40:588.
64. 64 Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, et al.: CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 1999, 80:364-370.
65. 65 Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM: Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 1998, 18:3499-3506.
66. 66 Barrows LR, Holden JA, Anderson M, D'Arpa P: The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutation Res 1998, 408:103-110.
67. 67 Potter PM, Pawlik CA, Morton CL, Danks MK: Isolation and partial characterization of a carboxylesterase that converts CPT-11 to SN-38. Cancer Res 1998, 58:2646-2651.
68. 68 Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, et al.: Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999, 5:917-924.
69. 69 Gupta M, Fujimori A, Pommier Y: Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995, 1262:1-14.
70. 70 Lue N, Sharma A, Mondragon A, Wang JC: A 26 kDa yeast DNA topoisomerase I fragment; crystallographic structure and mechanistic implications. Structure 1995, 3:1315-1322.